Uncovering The Genetics Of Prostate Cancer
1/22/2011
Prostate cancer is known to occur typically in older men. Yet some patients are younger than 50 years at the time of diagnosis. Scientists assume that these cases might be the key to understanding the biology of this disease. Early prostate cancer might be a subtype which is characterized by a relatively small number of genetic modifications...
4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company, announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer...
'Patchwork' Of Gene Faults Could Help Predict Cervical Cancer Drug Success
1/20/2011
Cancer Research UK scientists have discovered that cervical cancer patients who have a mixture of different genetic faults in their tumour at the start of treatment may be more likely to relapse, according to a study published in the British Journal of Cancer...
Survivors' Stories, Statistics, Highlight Importance Of Cervical Cancer Elimination Goal
1/20/2011
Patricia Gregory of Cary was only 24 years old when she was diagnosed with cervical cancer. Now a mother of an 11-year-old daughter, she considers herself blessed to have a child, as cervical cancer can make women unable to bear children. Marie Miranda, who was diagnosed at age 28, underwent a total hysterectomy. "I was heartbroken ...
Kidney Cancer: Same Gene Mutation In One Third Of Common Cases
1/20/2011
One third of the most common forms of kidney cancer (clear cell renal cell carcinoma, ccRCC) involves a mutation of the same gene, called PBRM1, an international team of researchers wrote in in a leading journal this week...
Merck Serono: Erbitux Long-Term Survival Benefit For mCRC Patients Confirmed With FOLFOX
1/20/2011
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUSa study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOL...
New Advances Aimed At Improving Treatment Of Gastrointestinal Cancers
1/20/2011
New research into the treatment of gastrointestinal cancers - and novel ways to predict recurrence and response to chemotherapy - was released in advance of the eighth annual Gastrointestinal Cancers Symposium, which will be held January 20-22, 2011, at The Moscone West Building in San Francisco, Ca...
Study Details How Protein Made By HPV Teams Up On And Thwarts Protective Human Protein
1/13/2011
An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection...
Ovarian Cancer Charities Work Together For Awareness Month
1/11/2011
Ovarian cancer charities are working together for the first time during Ovarian Cancer Awareness Month (March 2011) to build awareness of signs and symptoms of ovarian cancer...
Melanoma, Ovarian, And Prostate Cancer Treatment Guidelines For Patients Available From NCCN
1/09/2011
People with melanoma, ovarian cancer, or prostate cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options...